Cancer Immunology – Multimedia

A vaccine which targets an aggressive form of breast cancer is moving forward to a second trial involving patients fighting cancer.

Download this infographic to discover the impact of the immune system and inflammation on cancer development, how these effects change as cancers become more advanced and how we can use therapies to exploit them.

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and promising approach for cancer treatment. However, its potential is limited by technical challenges and safety risks associated with viral transduction–based CAR T-cell generation workflows.

Immunotherapy using immune checkpoint inhibitors (ICI) has revolutionized the treatment landscape in oncology, but significant challenges remain. Without reliable tools to identify likely responders, patients who may have responded are not prescribed ICIs.

It has proven difficult to accurately identify the biological targets of cancer, which are necessary for the development of successful therapeutics including novel immunotherapies, such as those based on chimeric antigen receptor (CAR) T cells.

This listicle highlights five commonly used cell viability assays and their benefits and limitations in immunotherapy potency testing.

Speaking at The Landscape of Cancer Research 2021 online symposium, Tianzi Li delivered her talk on the discovery of novel targets and the use of antibodies in cancer therapy.

The clinical success of CAR T-cell therapy has spurred increased interest and investments in the advanced therapeutics industry.

While CRISPR-edited cell lines can be beneficial for target identification, reagent validation, and biomarker discovery, generating high-quality cell lines can be fraught with difficulties and time-consuming and relies on several factors.

Speaking in June 2021 at the online symposium, Advances in Proteomics & Metabolomics, Dr. Genevieve Van de Bittner, R&D Researcher at Agilent Research Laboratories presented her talk on metabolic rate measurements using Seahorse XF and LC/MS technologies.